Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Neurology
•
Neuro-immunology
When do you consider disease modifying therapy in radiographically isolated syndrome?
Does reclassification of RIS as MS in upcoming McDonald Criteria change this decision for you?
Related Questions
What is the role of skin biopsy for evaluating small fiber neuropathy in patients with rheumatic disease who have treatment recalcitrant pain?
Can you use a JAK inhibitor and Mavenclad in a patient with both multiple sclerosis and rheumatoid arthritis?
How do you decide on long term immunosuppression therapy for Susac Syndrome?
How can we minimize the risk of overinterpreting reactive findings from repeat lumbar punctures?
What criteria do you use to differentiate between MOGAD and MS in pediatric patients?
How do you mitigate the risk of rebound disease activity when discontinuing S1p inhibitors or Tysabri in patients with multiple sclerosis?
What is your initial treatment paradigm for someone with both CNS and peripheral neurologic Sjogren’s?
For patients on anti-CD20 therapy for MS without frequent/opportunistic infections, are there serum IgG levels or ALC levels in which you pause or change therapy due to low levels?
What therapy do you recommend in situations where IV steroids and IVIg do not help patients with GABA-A encephalitis?
What is the diagnostic approach and management for suspected Hashimoto Encephalitis?